QIAGEN Announces Supply Agreement with Veridex, LLC to Provide GeneSearch™ Sample Preparation Kits
Apr 18 2005

QIAGEN Announces Supply Agreement with Veridex, LLC to Provide GeneSearch™ Sample Preparation Kits

Venlo, the Netherlands; April 18, 2005: QIAGEN N.V. (Nasdaq: QGEN, Frankfurt, Prime Standard: QIA) today announced that its wholly owned subsidiary QIAGEN GmbH has entered into a manufacturing and supply agreement with Veridex, LLC, a Johnson & Johnson company. Veridex intends to market QIAGEN's preanalytical solutions under their GeneSearch trademark and as a component of the diagnostics solutions offered by Veridex.

This customized kit will incorporate a custom version of QIAGEN's market and technology leading RNeasy® technology for rapid and reliable purification of RNA from lymph node specimens excised for simultaneous oncology testing and monitoring during surgery. QIAGEN's proprietary nucleic acid sample preparation and handling standards provide highest reliability and efficiency in both DNA and RNA separation and purification for molecular diagnostics applications.

"We are pleased to be supporting Veridex with QIAGEN nucleic acid purification and handling solutions for their amplification and detection procedure," said Dr. Frank Krieg-Schneider, Executive Director Strategic Alliances at QIAGEN. "The intra-operative PCR-based oncology testing solutions from Veridex are considered to be some of the most promising molecular diagnostic testing products in the marketplace. Efficient handling, processing, extraction and purification of such often rare target nucleic acids are important success factors for sensitive and reliable nucleic acid testing."


QIAGEN N.V., a Netherlands holding company with subsidiaries in Germany, the United States, Japan, the United Kingdom, Switzerland, France, Italy, Australia, Norway, Austria, Canada, and the Netherlands believes it is the world's leading provider of innovative enabling technologies and products for the separation, purification and handling of nucleic acids and proteins. QIAGEN has developed a comprehensive portfolio of more than 320 proprietary, consumable products for nucleic acid and protein separation, purification and handling, nucleic acid amplification, as well as automated instrumentation, synthetic nucleic acid products and related services. QIAGEN's products are sold in more than 42 countries throughout the world to academic research markets and to leading pharmaceutical and biotechnology companies. In addition, QIAGEN is positioning its products for sale into developing commercial markets, including DNA sequencing and genomics, nucleic acid-based molecular diagnostics, and genetic vaccination and gene therapy. QIAGEN employs approximately 1,400 people worldwide. Further information on QIAGEN can be found at http://www.qiagen.com/.


Certain of the statements contained in this news release may be considered forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amended. To the extent that any of the statements contained herein relating to QIAGEN's products, markets, strategy or operating results are forward-looking, such statements are based on current expectations that involve a number of uncertainties and risks. Such uncertainties and risks include, but are not limited to, risks associated with management of growth and international operations (including the effects of currency fluctuations and risks of dependency on logistics), variability of operating results, the commercial development of the DNA sequencing, genomics and proteomics markets, nucleic acid-based molecular diagnostics market, and genetic vaccination and gene therapy markets, competition, rapid or unexpected changes in technologies, fluctuations in demand for QIAGEN's, products (including seasonal fluctuations), difficulties in successfully adapting QIAGEN's products to integrated solutions and producing such products, the ability of QIAGEN to identify and develop new products and to differentiate its products from competitors, market acceptance of QIAGEN's new products and the integration of acquisitions of technologies and businesses. For further information, refer to the discussion in reports that QIAGEN has filed with, or furnished to, the U.S. Securities and Exchange Commission (SEC).







Phone: +49 2103 29 11710

Fax: +49 2103 29 21710

Email: ir@qiagen.com


Share this page